Posts Tagged ‘Crohn’s Disease

The patient demographics and characteristics did not differ significantly between responders and nonresponders (Table 3). Furthermore, response rates did not differ between those with and those without concomitant immune modifiers (75% and 71%, respectively; P=0.568), or with the number of infliximab infusions used for induction (one-, two- or three-dose infliximab: 73%, 100% and 73%, respectively; […]

Infliximab-induced clinical response The clinical outcomes of the 109 patients are shown in Table 2. The median time to response was two weeks (range one to six weeks), and the median duration of response was 12 weeks (range six to 88 weeks). Overall, a clinical response (complete or partial as defined above in the ‘Methods’) […]

Patient characteristics A total of 109 patients, 57 men and 52 women treated by 13 gastroenterologists, were included in the study. The median age was 42.5 years (range 18 to 79 years). Patient demographic characteristics, including previous and current medical and surgical therapy, and concomitant medical treatment are summarized in Table 1. Indications for infliximab […]

Infliximab was administered as a 5 mg/kg intravenous infusion; no patients received 10 mg/kg infusions. The type of induction used was at the treating physician’s discretion, as was the administration of subsequent doses and their timing. Patients with inflammatory disease received a single induction dose, while those with fistulizing disease received three induction doses at […]

Infliximab was available either through compassionate release or through clinical trials. All gastroenterologists in Edmonton were contacted to determine whether they had treated patients with infliximab. Records of patients who had received infliximab via compassionate release programs (n=101) were reviewed, as were the records of patients who had received an initial dose of infliximab as […]

Inflammatory bowel disease (IBD) is the result of an unchecked intestinal inflammatory response. While the exact etiology and pathogenesis of IBD are unclear, the inflammatory response is likely initiated by luminal factors, likely bacteria or bacterial products that serve as activating antigens. By sieving through a permeable epithelial barrier, these initiating factors in turn lead […]

An ideal drug in the management of IBD fistula would treat the disease as well as the fistula; have a rapid onset of action; induce long term remission; be safe, easy to administrate and monitor; and be cost effective. No single drug can achieve all of these goals. The best management strategy is to induce […]

top